Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$35.29 USD
-1.61 (-4.36%)
Updated Aug 7, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
JANX 35.29 -1.61(-4.36%)
Will JANX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JANX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JANX
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
JANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
Other News for JANX
Janux Therapeutics GAAP EPS of -$0.11 beats by $0.21, revenue of $8.89M beats by $8.03M
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
TD Cowen Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
Janux Therapeutics reports Q2 EPS (11c), consensus (31c)